BACKGROUND AND PURPOSE: Pseudoprogression is a frequent phenomenon observed since the introduction of postoperative therapy with radiotherapy and temozolomide (RT/TMZ) in glioblastoma multiforme (GBM) patients. However, the criteria defining pseudoprogression, its incidence, the time of occurrence and its impact on therapy and outcome remain poorly defined. METHODS: The objective of this study is to compare two sets of criteria (liberal and stringent), defining pseudoprogression, in a cohort of patients treated before and after the introduction of RT/TMZ in the standard postoperative treatment. This retrospective review includes 136 unselected and consecutively treated patients with pathologically diagnosed GBM. RESULTS: Pseudoprogression was observed in 10 (12%) cases applying the stringent criteria, and in 18 (23%) patients when using the liberal criteria, in the cohort treated with RT/TMZ. Pseudoprogression was observed in only one patient treated with RT alone. The median time to pseudoprogression was 4 weeks after the end of RT. Patients with pseudoprogression had a median survival time of 28 months, compared with 12 months for patients without pseudoprogression. CONCLUSIONS: The incidence of pseudoprogression after RT/TMZ strongly depends on the applied criteria. However, regardless of the stringency of the criteria, the impact on survival remains the same.
BACKGROUND AND PURPOSE: Pseudoprogression is a frequent phenomenon observed since the introduction of postoperative therapy with radiotherapy and temozolomide (RT/TMZ) in glioblastoma multiforme (GBM) patients. However, the criteria defining pseudoprogression, its incidence, the time of occurrence and its impact on therapy and outcome remain poorly defined. METHODS: The objective of this study is to compare two sets of criteria (liberal and stringent), defining pseudoprogression, in a cohort of patients treated before and after the introduction of RT/TMZ in the standard postoperative treatment. This retrospective review includes 136 unselected and consecutively treated patients with pathologically diagnosed GBM. RESULTS: Pseudoprogression was observed in 10 (12%) cases applying the stringent criteria, and in 18 (23%) patients when using the liberal criteria, in the cohort treated with RT/TMZ. Pseudoprogression was observed in only one patient treated with RT alone. The median time to pseudoprogression was 4 weeks after the end of RT. Patients with pseudoprogression had a median survival time of 28 months, compared with 12 months for patients without pseudoprogression. CONCLUSIONS: The incidence of pseudoprogression after RT/TMZ strongly depends on the applied criteria. However, regardless of the stringency of the criteria, the impact on survival remains the same.
Authors: Jerrold L Boxerman; Zheng Zhang; Yair Safriel; Jeffrey M Rogg; Ronald L Wolf; Suyash Mohan; Helga Marques; A Gregory Sorensen; Mark R Gilbert; Daniel P Barboriak Journal: Neuro Oncol Date: 2018-09-03 Impact factor: 12.300
Authors: Jayashree Kalpathy-Cramer; Elizabeth R Gerstner; Kyrre E Emblem; Ovidiu Andronesi; Bruce Rosen Journal: Cancer Res Date: 2014-09-01 Impact factor: 12.701
Authors: Yuxuan Wang; Simeon Springer; Ming Zhang; K Wyatt McMahon; Isaac Kinde; Lisa Dobbyn; Janine Ptak; Henry Brem; Kaisorn Chaichana; Gary L Gallia; Ziya L Gokaslan; Mari L Groves; George I Jallo; Michael Lim; Alessandro Olivi; Alfredo Quinones-Hinojosa; Daniele Rigamonti; Greg J Riggins; Daniel M Sciubba; Jon D Weingart; Jean-Paul Wolinsky; Xiaobu Ye; Sueli Mieko Oba-Shinjo; Suely K N Marie; Matthias Holdhoff; Nishant Agrawal; Luis A Diaz; Nickolas Papadopoulos; Kenneth W Kinzler; Bert Vogelstein; Chetan Bettegowda Journal: Proc Natl Acad Sci U S A Date: 2015-07-20 Impact factor: 11.205
Authors: Ramon F Barajas; Bronwyn E Hamilton; Daniel Schwartz; Heather L McConnell; David R Pettersson; Andrea Horvath; Laszlo Szidonya; Csanad G Varallyay; Jenny Firkins; Jerry J Jaboin; Charlotte D Kubicky; Ahmed M Raslan; Aclan Dogan; Justin S Cetas; Jeremy Ciporen; Seunggu J Han; Prakash Ambady; Leslie L Muldoon; Randy Woltjer; William D Rooney; Edward A Neuwelt Journal: Neuro Oncol Date: 2019-03-18 Impact factor: 12.300
Authors: Benjamin M Ellingson; Lauren E Abrey; Josep Garcia; Olivier Chinot; Wolfgang Wick; Frank Saran; Ryo Nishikawa; Roger Henriksson; Warren P Mason; Robert J Harris; Kevin Leu; Davis C Woodworth; Arnav Mehta; Catalina Raymond; Ararat Chakhoyan; Whitney B Pope; Timothy F Cloughesy Journal: Neuro Oncol Date: 2018-10-09 Impact factor: 12.300
Authors: Homan Mohammadi; Kevin Shiue; G Daniel Grass; Vivek Verma; Kay Engellandt; Dirk Daubner; Gabriele Schackert; Mercia J Gondim; Dibson Gondim; Alexander O Vortmeyer; Aaron P Kamer; William Jin; Timothy J Robinson; Gordon Watson; Hsiang-Hsuan M Yu; Tim Lautenschlaeger Journal: Neurooncol Pract Date: 2019-10-10